FRI0401 EFFECT OF LONG-TERM TREATMENT WITH SECUKINUMAB ON LIPID PROFILE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS: POOLED 4 YEAR ANALYSIS
Authors: Iain McInnes, Dafna D. Gladman, Atul Deodhar, Corinne Miceli Richard, Peter Nash, Abhijit Shete, Daren Asquith, Hanno Richards, Luminita Pricop, Jianyuan Wang
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Systemic inflammation may adversely affect the lipid profile in AS and PsA patients (pts)<sup>1</sup>. Treatment with some TNF and JAK inhibitors have reported increased total cholesterol (TC) and triglycerides (TG) despite reduction in inflammation<sup>2-3</sup>. Secukinumab (SEC), a fully human monoclonal antibody that directly inhibits IL-17A, has demonstrated a sustained efficacy and consistent safety profile in pts with AS and PsA<sup>4</sup> <h3>Objectives</h3> To evaluate the long-term effect of SEC on key lipid parameters in AS and PsA pts from pooled phase 3 clinical trials, through 208 weeks (wks) <h3>Methods</h3> This <i>post hoc</i> analysis included pooled data from MEASURE 1-4 (SEC 150 mg) in AS (N = 892) and FUTURE 2-5 studies (SEC 150/300 mg) in PsA (N = 2049), from pts treated with SEC or placebo (PBO). Serum TC, TG, LDL- and HDL-cholesterol and TC/HDL-C levels were assessed at baseline (BL), Wks 16, 104 and 208 in overall population and in sub-groups by prior anti-TNF therapy, concomitant methotrexate (MTX) and BL statin usage. Shift of common terminology criteria for adverse events (CTCAE) grade from BL through Wk 208 were also analysed <h3>Results</h3> BL characteristics were comparable across SEC and PBO groups. Lipid levels were stable in SEC treated AS and PsA pts through Wk 208 (<b>Table</b>) with mean change (mmol/L) from BL in AS: TC = ±0.1, TG = 0.1-0.2, LDL-C = ±0.1, HDL-C = ±0.04 and TC/HDL-C = ±0.2 and PsA: TC = ±0.2, TG = 0.001-0.2, LDL-C = ±0.2, HDL-C = ±0.06 and TC/HDL-C = ±0.2. Stable lipid values were also seen across key sub-groups by prior anti-TNF therapy, concomitant MTX and BL statin usage, which remained stable through Wk 208. No Change in CTCAE lipid grades was observed in &gt;90% of SEC-treated pts through Wk 208 <h3>Conclusion</h3> SEC did not adversely affect the lipid profile and TC/HDL-C ratio in pts with AS and PsA, over 4 years. The lipid profile remained stable with SEC treatment and was sustained irrespective of prior anti-TNF status, concomitant MTX and BL statin usage <h3>References</h3> [1] Papagoras C, et al. Joint Bone Spine2014;81:57-63 [2] Wolk R, et al. J Clin Lipidol.. 2017;11:1243-56 [3] Agca R, et al. J Rheumatol. 2017; 44(9):1362-8 [4] Lubrano E and Perrotta FM. Ther Clin Risk Manag. 2016;12:1587-92 <h3>Disclosure of Interests</h3> Iain McInnes Grant/research support from: AstraZeneca, Celgene, Compugen, Novartis, Roche, UCB Pharma, Consultant for: AbbVie, Celgene, Galvani, Lilly, Novartis, Pfizer, UCB Pharma, Dafna D Gladman Grant/research support from: AbbVie, Amgen, Celgene, Lilly, Novartis, Pfizer, and UCB, Consultant for: AbbVie, Amgen, BMS, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB, Atul Deodhar Grant/research support from: AbbVie, Amgen, Eli Lilly, GSK, Janssen, Novartis, Pfizer, and UCB, Consultant for: AbbVie, Amgen, BMS, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Corinne Miceli Richard Grant/research support from: MSD, Pfizer, AbbVie, Biogen, UCB, Novartis, Consultant for: Abbvie, Novartis, BMS, Peter Nash Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Consultant for: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Abhijit Shete Shareholder of: Novartis Pharma AG, Employee of: Novartis Pharma AG, Daren Asquith Shareholder of: Novartis Pharma AG, Employee of: Novartis Pharma AG, Hanno Richards Shareholder of: Novartis Pharma AG, Employee of: Novartis Pharma AG, Luminita Pricop Shareholder of: Novartis, Employee of: Novartis, Jianyuan Wang Employee of: Novartis